Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Telbivudine: a review of its use in compensated chronic hepatitis B.

McKeage K, Keam SJ.

Drugs. 2010 Oct 1;70(14):1857-83. doi: 10.2165/11204330-000000000-00000. Review.

PMID:
20836578
3.

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J.

Hepatology. 2008 Feb;47(2):447-54.

PMID:
18080339
4.

Telbivudine versus lamivudine in patients with chronic hepatitis B.

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group.

N Engl J Med. 2007 Dec 20;357(25):2576-88.

5.

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV; GLOBE Study Group.

Gastroenterology. 2009 Feb;136(2):486-95. doi: 10.1053/j.gastro.2008.10.026. Epub 2008 Nov 1.

PMID:
19027013
6.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
7.

[The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].

Moon YM, Hwang SG, Kim BS, Rim KS, Cho M, Kim DJ, Han JY, Kim YS, Choi HS, Ahn SH.

Korean J Hepatol. 2007 Dec;13(4):503-12. Korean.

8.

Telbivudine for the treatment of chronic hepatitis B infection.

Hartwell D, Jones J, Harris P, Cooper K.

Health Technol Assess. 2009 Oct;13 Suppl 3:23-30. doi: 10.3310/hta13suppl3/04. Review.

9.

[Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].

Liang J, Han T, Xiao SX.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jan;17(1):24-7. Chinese.

PMID:
19203447
10.

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.

Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group.

Ann Intern Med. 2007 Dec 4;147(11):745-54. Epub 2007 Oct 1.

PMID:
17909201
11.

Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.

Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF.

J Hepatol. 2011 Sep;55(3):522-8. doi: 10.1016/j.jhep.2010.11.018. Epub 2010 Dec 13.

PMID:
21147187
12.

Telbivudine for the management of chronic hepatitis B virus infection.

Matthews SJ.

Clin Ther. 2007 Dec;29(12):2635-53. doi: 10.1016/j.clinthera.2007.12.032. Review.

PMID:
18201580
13.

A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.

Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.

J Antimicrob Chemother. 2012 Mar;67(3):696-9. doi: 10.1093/jac/dkr495. Epub 2011 Dec 15.

14.

Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.

Hann HW.

Expert Opin Pharmacother. 2010 Sep;11(13):2243-9. doi: 10.1517/14656566.2010.512437. Review.

PMID:
20698726
15.

Telbivudine in the treatment of chronic hepatitis B.

Nash K.

Adv Ther. 2009 Feb;26(2):155-69. doi: 10.1007/s12325-009-0004-y. Epub 2009 Feb 18. Review.

PMID:
19225726
16.

[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].

Jia JD, Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ, Zhou XQ, Wang YM, Zhu LM, He YW, Ren H, Wan MB, Chen CW, Wu SM, Chen YG, Xu JZ, Wang QH, Wei L, Ma H.

Zhonghua Gan Zang Bing Za Zhi. 2007 May;15(5):342-5. Chinese.

PMID:
17524265
17.

Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.

Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P, Lee HC, Avila C, Zeuzem S.

Antimicrob Agents Chemother. 2010 Mar;54(3):1242-7. doi: 10.1128/AAC.01163-09. Epub 2009 Dec 22.

18.

Telbivudine.

Keam SJ.

Drugs. 2007;67(13):1917-29. Review.

PMID:
17722961
19.

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.

Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C.

Liver Int. 2011 May;31(5):676-84. doi: 10.1111/j.1478-3231.2011.02490.x. Epub 2011 Mar 16.

PMID:
21457439
20.

Treatment of chronic hepatitis B: focus on telbivudine.

Lui YY, Chan HL.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):259-68. doi: 10.1586/eri.09.6. Review.

PMID:
19344240
Items per page

Supplemental Content

Write to the Help Desk